82 / 154
408
7. Sampson J. Alternating Electric Fields for the Treatment of
Glioblastoma (Editorial) JAMA 2015; 314 (23): 2511-2513
8. Cobbs C, Harkins L, Samanta M, et al. Human cytomegalovirus
infection and expression in human malignant glioma.
Cancer Res. 2002;62(12):3347–3350
9. Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in
patients with glioblastoma receiving valganciclovir. N Engl
J Med. 2013;369:985–986
10. Wick W, Michael Platten M. CMV infection and glioma, a
highly controversial concept struggling in the clinical arena.
Neuro Oncol 2014;16(3): 332–333.
11. Solomon I, Ramkissoon S, MD, Milner D, Folkerth R.
Cytomegalovirus and Glioblastoma: A Review of Evidencefor
Their Association and Indications for Testing and Treatment.
J Neuropathol Exp Neurol 2014; 73(11): 994-998
12. Chamberlain M. Emerging Clinical Principles on the Use
of Bevacizumab for the Treatment ofMalignant Gliomas.
Cancer 2010;116:3988–99.
13. Friedman H, Prados M, Wen P, et al. Bevacizumab alone and
in combination with irinotecan in recurrent glioblastoma.
JCO 2009; 27: 4733-4740
14. Potthast L, Chowdhary S, Pan E, Yu D, Zhu W, Brem S.The
infiltrative, diffuse pattern of recurrence in patientswith
malignant gliomas treated with bevacizumab [abstract].J
Clin Oncol. 2009;27(suppl 5):101s. Abstract 2057.
15. Brandes A, Mason W, Pichler J, et al. Can bevacizumab
prolong survival for glioblastoma patients through multiple
lines of therapy? Future Oncol. 2014;10(7):1137-45
16. Gilbert M, Dignam J, Armstrong T, et al. A randomized trial
of bevacizumab for newly diagnosed glioblastoma. N Engl J
Med. 2014; 370(8):699–708
17. Chinot O, Wick W, Mason W, et al. Bevacizumab plus
radiotherapy-temozolomide
for
newly
diagnosed
glioblastoma. N Engl J Med. 2014; 370(8):709–22
18. Batchelor T, Mulholland P, Neyns B, et al. Phase III
randomized trial comparing the efficacy of cediranib as
monotherapy, and in combination with lomustine, versus
lomustine alone in patients with recurrent glioblastoma.J
Clin Oncol. 2013; 31(26):3212-8
19. Wick W, Puduvalli V, Chamberlain M, et al. Phase III
study of enzastaurin compared with lomustine in the
treatment of recurrent intracranial glioblastoma. J Clin
Oncol.;28(7):1168-74
20. Nabors L, Fink K, Mikkelsen T, et al. Two cilengitide regimens
in combination with standard treatment for patients with
newly diagnosed glioblastoma and unmethylatedMGMT gene
promoter: results of the open-label, controlled, randomized
phase II CORE study. Neuro Oncol. 2015;17(5):708-17
21. Stupp R, Hegi M, Gorlia T, et al. Cilengitide combined
with standard treatment for patients with newly
diagnosed glioblastoma with methylated MGMT promoter
(CENTRIC EORTC 26071-22072 study): a multicentre,
randomised, open-label, phase 3 trial. Lancet Oncol.
2014;15(10):1100-8.
22. Van Meir E, Hadjipanayis C, Norden A, et al. Exciting New
Advances in Neuro-Oncology.The Avenue to a Cure for
Malignant Glioma. CA Cancer J Clin 2010;60:166-193.
23. Reardon D, Schuster J, Tran D, et al. ReACT: overall survival
from a randomized phase II study of rindopepimut (CDX-
110) plus bevacizumab in relapsed glioblastoma J. Clin.
Oncol 2015; 33 (15 S) (suppl): abstr 2009.
24. Elamin Y, Rafee S, Toomey S, Hennessy B. Immune Effects
of Bevacizumab: Killing Two Birds with One Stone. Cancer
Microenviron. 2015; 8(1): 15–21
25. Prins R, Soto H, Konkankit V, et al.Gene expression profile
correlates with T-cell infiltration and relative survival
in glioblastoma patients vaccinated with dendritic cell
immunotherapy. Clin Cancer Res. 2011;17(6):1603-15
26. Polyzoidis S1, Ashkan K. DCVax®-L--developed by
Northwest Biotherapeutics. Hum Vaccin Immunother.
2014;10(11):3139-45
27. Carter T, Shaw H, Cohn-Brown D, Chester K, Mulholland
P.Ipilimumab and Bevacizumab in Glioblastoma. Clin Oncol
(R Coll Radiol). 2016;28(10):622-6
28. Sampson J, Vlahovic G, Sahebjam S. Preliminary safety and
activity of nivolumab and its combination with ipilimumab
in recurrent glioblastoma (GBM): CHECKMATE-143. Journal
of Clinical Oncology 2015; 33 (15 S) (suppl): abstr 3010
29. Curry W, Lim M. Immunomodulation: checkpoint blockade
etc. Neuro-Oncology 2015; 17: vii26–vii31
30. Desjardins A, Sampson J, Peters K, et al. Oncolytic polio/
rhinovirus recombinant (PVSRIPO) against recurrent
glioblastoma (GBM): Optimal dose determination. J Clin
Oncol. 2015;33 (15 S) (suppl): abstr 2068
31. Goetz C, Gromeier M. Preparing an Oncolytic Poliovirus
Recombinant for Clinical Application Against Glioblastoma
Multiforme. Cytokine Growth Factor Rev. 2010; 21:197–
203.
32. Lang F, Conrad C, Gomez-Manzano C, et al. Phase I clinical
trial of oncolytic virus Delta-24-RGD (DNX-2401) with
biological endpoints: implications for viro-immunotherapy.
Neuro-Oncology 2014; 16 (issue suppl_5): v162-v162
33. Markert J, Razdan S, Kuo H, et al. A phase 1 trial of oncolytic
HSV-1, G207, given in combination with radiation for
recurrent GBM demonstrates safety and radiographic
responses. Mol Ther. 2014; 22:1048-55.
34. Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study
of intratumoral/intracerebral or intravenous/intracerebral
administration of Parvovirus H-1 (ParvOryx) in patients with
progressive primary or recurrent glioblastoma multiforme:
ParvOryx01 protocol. BMC Cancer 2012; 12:99.
35. Rainov N. A phase III clinical evaluation of herpes simplex
virus type 1 thymidine kinase and ganciclovir gene therapy
as an adjuvant to surgical resection and radiation in adults
with previously untreated glioblastoma multiforme. Hum
Gene Ther. 2000; 11(17):2389-401.
36. Okura H, Smith C, Rutka J. Gene therapy for malignant
glioma. Mol Cell Ther. 2014; 2: 21.
[REV. MED. CLIN. CONDES - 2017; 28(3) 401-408]